Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» SNTS's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SNTS Guru Trades in Q2 2013

Jim Simons 2,684,843 sh (+5.33%)
Paul Tudor Jones 11,600 sh (-1.69%)
Steven Cohen 10,940 sh (-68.37%)
» More
Q3 2013

SNTS Guru Trades in Q3 2013

Joel Greenblatt 66,922 sh (New)
Steven Cohen 79,817 sh (+629.59%)
Paul Tudor Jones 23,000 sh (+98.28%)
Jim Simons 2,142,938 sh (-20.18%)
» More
Q4 2013

SNTS Guru Trades in Q4 2013

John Paulson 5,000,000 sh (New)
Mario Gabelli 392,700 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 2,136,038 sh (-0.32%)
Joel Greenblatt 25,257 sh (-62.26%)
» More
Q1 2014

SNTS Guru Trades in Q1 2014

Jim Simons Sold Out
John Paulson Sold Out
Mario Gabelli Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Santarus, Inc.

Mario Gabelli Comments on Valassis Communications - Apr 30, 2014

Valassis Communications Inc. (VCI) is a Michigan based media and advertising company specializing in direct marketing services. On December 18, 2013, the company received a $34.04 cash tender offer from Harland Clarke Holdings Corp., a private marketing and integrated payment solutions provider located in San Antonio, Texas. The deal closed in early February after receiving the necessary minimum condition and regulatory approvals. The Fund earned a 4.18% return.

From Mario Gabelli (Trades, Portfolio)'s first quarter 2014 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Santarus, Inc.



Valuation & Return


Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TW4A.Germany,
Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial